RxDoctor Payments Data

Grace Lin, MD

Nephrology · Whittier, CANPI 1114167178

Payments from drug & device makers

$954in general payments, 2019–2025

Across 27 payments — averaging $35.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$346
  • Otsuka America Pharmaceutical, Inc.$148
  • Novartis$105
  • Akebia Therapeutics Inc$84
  • Calliditas Therapeutics US Inc.$41
  • Fresenius USA Marketing, Inc.$36
  • plus $194 from 9 others

What the payments were for

  • Food & beverage$954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$954 in reported general payments places this provider in the 45th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$183,324
Medicare patients
374
Services billed
1,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$50,252
JanuviaSitagliptin Phosphate24$35,280
LokelmaSodium Zirconium Cyclosilicate84$30,734
EliquisApixaban17$16,574
VeltassaPatiromer Calcium Sorbitex11$9,366
KerendiaFinerenone15$9,091
Tolvaptan11$4,501
Calcium Acetate43$3,172
Sevelamer Carbonate14$1,696
Labetalol Hcl27$1,214
ProcritEpoetin Alfa11$1,203
Nifedipine ErNifedipine24$860
Hydralazine Hcl52$812
Losartan Potassium63$653
Gabapentin13$650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$346$80,986167 claims
MerckJanuvia$19$35,28024 claims
BayerKerendia$18$9,09115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,341 nephrology providers in California.

Other nephrology in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →